Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Amanita phalloides Mushroom Poisonings — Northern California, December 2016

Kathy T. Vo, MD1,2; Martha E. Montgomery, MD3; S. Todd Mitchell, MD4; Pieter H. Scheerlinck, MD5,6; Daniel K. Colby, MD5,6; Kathryn H. Meier, PharmD2,7; Susan Kim-Katz, PharmD2,7; Ilene B. Anderson, PharmD2,7; Steven R. Offerman, MD8; Kent R. Olson, MD2; Craig G. Smollin, MD1,2 (View author affiliations)

View suggested citation


What is already known about this topic?

Ingestion of Amanita phalloides is responsible for a majority of mushroom-related deaths worldwide. Amatoxins, the principal toxic alkaloids found in these fungi, cause cell injury by halting protein synthesis. A possible antidote licensed in most of Europe, intravenous silibinin, is undergoing evaluation by clinical trial in the United States.

What is added by this report?

In December 2016, fourteen cases of Amanita phalloides poisoning were identified by the California Poison Control System (CPCS) among persons who had consumed foraged wild mushrooms. In the past few years before this outbreak, CPCS only received reports of a few mushroom poisoning cases per year. All patients in this outbreak had gastrointestinal manifestations of intoxication leading to dehydration and hepatotoxicity. Three patients received liver transplants; all patients recovered, although one (a child) had permanent neurologic impairment.

What are the implications for public health practice?

Wild-picked mushrooms should be evaluated by a trained mycologist before ingestion. Inexperienced foragers should be strongly discouraged from eating any wild mushrooms. Health care providers should be aware of the potential for toxicity after wild mushroom ingestion, that gastrointestinal symptoms mimicking viral gastroenteritis can occur after ingestion and slowly progress to potentially fatal hepatotoxicity, and should contact the local poison center for reporting and assistance with management of these patients.

Amanita phalloides, colloquially known as the “death cap,” belongs to the Phalloideae section of the Amanita family of mushrooms and is responsible for most deaths following ingestion of foraged mushrooms worldwide (1). On November 28, 2016, members of the Bay Area Mycological Society notified personnel at the California Poison Control System (CPCS) of an unusually large A. phalloides bloom in the greater San Francisco Bay Area, coincident with the abundant rainfall and recent warm weather. Five days later, CPCS received notification of the first human A. phalloides poisoning of the season. Over the following 2 weeks, CPCS was notified of an additional 13 cases of hepatotoxicity resulting from A. phalloides ingestion. In the past few years before this outbreak, CPCS received reports of only a few mushroom poisoning cases per year. A summary of 14 reported cases is presented here. Data extracted from patient medical charts revealed a pattern of delayed gastrointestinal manifestations of intoxication leading to dehydration and hepatotoxicity. Three patients received liver transplants and all but one recovered completely. The morbidity and potential lethality associated with A. phalloides ingestion are serious public health concerns and warrant medical provider education and dissemination of information cautioning against consuming foraged wild mushrooms.

Initial case. A man aged 37 years (patient A) picked two wild mushrooms in Santa Rosa, California (Table). He cooked and ate one mushroom, and approximately 10 hours later developed nausea, vomiting, and diarrhea. He was evaluated in a local emergency department (ED) for abdominal discomfort 20.5 hours after ingestion. A mycologist identified the uncooked mushroom sample provided by the patient as A. phalloides. Initial laboratory findings were notable for an elevated white blood cell count with lactate elevation and elevated creatinine suggesting dehydration (Table). Liver function tests (LFTs) 6 hours later showed elevated aspartate aminotransferase (AST) (92 IU/L; normal = 15–41) and alanine aminotransferase (ALT) (95 IU/L; normal = 17–63) levels. He was treated with aggressive intravenous (IV) fluid hydration, IV octreotide,* and IV silibinin. Two days after ingestion, the patient’s LFTs peaked at AST = 6,159 IU/L, ALT = 3,084 IU/L, total bilirubin = 2.9 mg/dL (normal = 0.2–1.2), and international normalized ratio (INR) (standardized prothrombin time) 3.2 units (normal = 0.8–1.2). Gastrointestinal symptoms and laboratory values gradually improved, and the patient was discharged home on day 6.

Household cluster. A woman aged 26 years (patient B) prepared and grilled wild mushrooms for dinner for her husband (patient C, 28 years), her daughter (patient D, 18 months), her sister (patient E, 38 years), and a female friend (patient F, 49 years). The mushrooms had been given to her by a person she did not know, who reportedly picked them earlier in the day in the mountains. The mother, father, and child ate four, three, and one-half mushroom caps, respectively; the mother’s sister ate one cap and stalk, and the friend ate “pieces.”

All persons who consumed the mushrooms developed nausea, vomiting, and diarrhea approximately 9 hours after ingestion. The mother, father and child (patients B, C, and D) visited the ED 20 hours after ingestion with dehydration and gastrointestinal distress. All patients had laboratory values consistent with hepatic injury (Table). The patients were treated with aggressive IV fluid hydration, IV octreotide, and IV silibinin. Two days after ingestion of the mushrooms, the mother’s LFTs peaked at AST 11,427, ALT 9,693, total bilirubin 2.4 mg/dL, and INR 3.2 units. The father’s LFTs peaked on hospital day 1 with AST 6,123 IU/L, ALT 4,401 IU/L, and total bilirubin 2.8 on hospital day 2. Both parents’ symptoms improved, and they were discharged on hospital days 6 and 4, respectively. The child developed irreversible fulminant hepatic failure and required mechanical ventilation because of hepatic encephalopathy. She underwent a liver transplant 6 days after ingestion of the mushroom with a complicated postoperative course that included cerebral edema and permanent neurologic impairment.

The sister of the woman who prepared the meal (patient E) visited the ED before her other family members, but was discharged home after administration of IV fluids and antiemetic medications, with a diagnosis of gastroenteritis. She returned to the ED the following day with persistent nausea, vomiting, diarrhea, and abdominal cramping. At that time, her AST was 1,712 IU/L, ALT 1,025 IU/L, total bilirubin 2.0 mg/dL, and INR 1.8 units. She was treated with aggressive IV fluid hydration, IV octreotide, and IV silibinin, as well as the placement of a biliary drain, but developed irreversible fulminant hepatic failure and underwent liver transplant on hospital day 4, with subsequent improvement of her hepatic function.

The family friend (patient F) visited an ED 2 days after ingestion of the mushrooms, complaining of abdominal pain, nausea, vomiting, and diarrhea. On hospital day 1, her LFTs peaked at AST 11,940, ALT 11,350, and INR 4.5. She was treated with aggressive IV fluid hydration, IV octreotide, and IV silibinin. Her hepatic function recovered, and she was discharged home on hospital day 6.

Additional cases. In the subsequent 2 weeks, CPCS was notified of eight additional cases of acute liver injury after consumption of wild mushrooms in northern California counties (Table). One case involved a man aged 36 years who had ingested mushrooms, later confirmed to be A. phalloides, obtained from a friend who picked them during a hike. Another case occurred in a man aged 56 years who was evaluated at an ED 2 days after ingestion of foraged mushrooms and required a liver transplant; two cases occurred in women aged 86 and 93 years who received wild-picked mushrooms from a friend; and four men aged 19–22 years who developed hepatotoxicity after ingesting what they thought were psychedelic mushrooms picked from the wild. Most of these patients had recovery of hepatic function.


Over the course of 2 weeks in December 2016, CPCS investigated 14 suspected A. phalloides ingestions in five northern California counties. Eleven patients recovered, although three required liver transplants because of irreversible fulminant hepatic failure. One of those patients, a child, developed cerebral edema and suffered permanent neurologic sequelae.

Amatoxins, consisting of alpha, beta, and gamma amanitin, account for >90% of deaths related to mushroom poisoning worldwide (1). A. phalloides contains the alpha variety of amanitin, a cyclic octapeptide thought to be the primary agent of toxicity in humans (2). The amanitins are heat stable and are not inactivated by cooking. Once ingested, amatoxin is readily absorbed from the gastrointestinal tract into the portal circulation where it is taken up by hepatocytes, binding to DNA-dependent RNA polymerase (II) and halting intracellular protein synthesis, ultimately resulting in cell death (3). A lethal dose can be as low as 0.1 mg/kg, and a single mushroom can contain up to 15 mg (1). The clinical course of amatoxin poisoning is described in three phases: delayed gastroenteritis with significant body fluid volume loss (after a postingestion latency of 6–24 hours), symptomatic recovery (24–36 hours after ingestion), and fulminant hepatic and multiorgan failure (typically 3–5 days after the ingestion) (4). Patients who are evaluated early in the course of their illness might be discharged home only to return later with indications of liver failure, contributing to the relatively high case fatality rate (10%–20%) (5,6). Initial treatment emphasizes early supportive care including aggressive fluid and electrolyte replacement. In the event of irreversible fulminant liver failure, liver transplant might be required. A variety of therapies including multidose activated charcoal, high-dose penicillin, N-acetylcysteine, cimetidine, biliary drainage, and octreotide have been attempted with no definitive evidence of efficacy. Uncontrolled observational studies of Amanita intoxication suggest that the early use of silibinin, a milk thistle derivative, is associated with a reduction in mortality when compared with historical controls (7); however, as with the other aforementioned therapies, evidence supporting efficacy is lacking because of difficulties associated with conducting randomized controlled trials. Intravenous silibinin is licensed in Europe, and a clinical trial to evaluate its efficacy in treatment of hepatic failure induced by Amanita mushroom poisoning is currently underway in the United States.§ The majority of silibinin-treated patients in this report received the drug as participants of this trial. Medical providers should contact the regional poison control center or a medical toxicology consultant to assist in the management of any patient with suspected amatoxic mushroom ingestion.

In California, A. phalloides species grow in a symbiotic relationship with coast live oak and other hardwood trees (8). They can be especially abundant in the early wet winter months, though the foggy coastal climate and warmer temperatures can support mushroom growth throughout the year (4). In 2016, local mycologists noted an abundance of wild mushroom growth, and California county health departments reported an increase in the incidence of mushroom poisoning (9). Although weather conditions and increased numbers of A. phalloides poisonings do not prove a cause and effect relationship, early seasonal rainfall and warmer subsequent temperatures made a substantial contribution to mushroom proliferation. In addition, a general increase in naïve foraging and wildcrafting (i.e., gathering plant material from its native environment for food or medicinal purposes) activities raises risk for poisoning.

Mycologists recommend exercising caution when foraging or purchasing wild mushrooms for consumption. If wild mushrooms are to be consumed, specimens should first be examined, identified, and deemed edible by an experienced mycologist (4). Prompt identification of mushroom-related toxic symptoms in the ED and early, aggressive IV volume replacement are critical first steps in diminishing the significant morbidity and mortality associated with amatoxin ingestion. Antidotal therapies might also be considered in conjunction with a consultant experienced in hepatotoxic mushroom poisoning. In patients with severe poisoning, early contact with the nearest liver transplant center is recommended. Response to this outbreak included the notification of the local counties and state department of public health, which subsequently issued a widely distributed press release (9). Measures to disseminate information regarding the dangers of A. phalloides ingestion are ongoing.

Corresponding author: Kathy T. Vo,, 415-643-3243.

1Department of Emergency Medicine, University of California, San Francisco; 2California Poison Control System, San Francisco Division; 3Department of Emergency Medicine, Alameda County Medical Center/Highland Hospital, Oakland, California; 4Department of Family Medicine, Dignity Health Dominican Hospital, Santa Cruz, California, 5Department of Emergency Medicine, University of California, Davis; 6California Poison Control System, Sacramento Division; 7Department of Clinical Pharmacy, University of California, San Francisco; 8Medical Toxicology Consultation Service, Kaiser Permanente Northern California.

* Octreotide, by preventing emptying of the gallbladder, might reduce recirculation of amatoxins in bile to the liver.

Silibinin dihemisuccinate, a milk thistle extract, competitively inhibits hepatic amatoxin uptake and enterohepatic recycling, and is available in the United States through an open clinical trial.

§ Intravenous Milk Thistle. (Silibinin-Legalon®SIL) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning.

Registration identifier NCT00915681.


  1. Block SS, Stephens RL, Barreto A, Murrill WA. Chemical identification of the Amanita toxin in mushrooms. Science 1955;121:505–6. CrossRef PubMed
  2. Wieland T, Wieland O. Chemistry and toxicology of the toxins of Amanita phalloides. Pharmacol Rev 1959;11:87–107. PubMed
  3. Wieland T. The toxic peptides from Amanita mushrooms. Int J Pept Protein Res 1983;22:257–76. CrossRef PubMed
  4. Olson KR, Pond SM, Seward J, Healey K, Woo OF, Becker CE. Amanita phalloides-type mushroom poisoning. West J Med 1982;137:282–9. PubMed
  5. Floersheim GL, Weber O, Tschumi P, Ulbrich M. Clinical death cap Amanita phalloides poisoning: prognostic factors and therapeutic measures (German). Schweiz Med Wochenschr 1982;112:1164–77. PubMed
  6. Santi L, Maggioli C, Mastroroberto M, Tufoni M, Napoli L, Caraceni P. Acute liver failure caused by Amanita phalloides poisoning. Int J Hepatol 2012;2012:487480. CrossRef PubMed
  7. Mengs U, Pohl RT, Mitchell T. Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol 2012;13:1964–70. CrossRef PubMed
  8. Pringle A, Adams RI, Cross HB, Bruns TD. The ectomycorrhizal fungus Amanita phalloides was introduced and is expanding its range on the west coast of North America. Mol Ecol 2009;18:817–33. CrossRef PubMed
  9. California Department of Public Health. Use caution when collecting, eating wild mushrooms, December 8, 2016. Sacramento, CA: California Department of Public Health; 2016.
Return to your place in the textTABLE. Demographic and clinical data for 14 patients reported to the California Poison Control System after Amanita phalloides ingestion — Northern California, December 2016
Patient Age (yr.) Sex Mushrooms ingested Ingestion to symptom onset (hrs) Ingestion to hospital admission (hrs) Initial lactate (mmol/L)* Initial BUN/Cr (mg/dL) Initial AST/ALT§ (U/L) Peak AST/ALT, INR (units) Hospitalization duration (days) Outcome
A 37 M 1 (stalk and cap) 10 20 5.2 27/1.4 31/40 3084/6159, 3.2 6 Recovered
B** 26 F 4 caps 9 20 5.87 21/0.64 51/45 11427/9693, 3.2 6 Recovered
C** 28 M 3 caps 9 23 2.98 20/1.46 444/454 6123/4401, 1.4 6 Recovered
D** 1.5 (18 mo.) F ½ cap 9 19 9.22 16/<0.38 70/47 14300/10200, 10.2 36 Liver transplant, permanent neurologic impairment
E**,†† 38 F 1 (stalk and cap) 9 48 7.0 24/0.8 1712/1025 9573/6239, 13.3 13 Liver transplant, recovered
F** 49 F “Pieces” 9 48 6.72 95/2.24 1038/1100 11940/11350, 4.5 6 Recovered
G 36 M ½ cap 7 12 1.5 18/0.6 32/29 1858/3526, 1.6 5 Recovered
H 56 M Multiple 8–10 cm caps 12 64 5.4 62/2.33 1599/3200 2820/5599, >13.3 16 Liver transplant, recovered
I 86 F Unknown Unknown ~48 Not drawn 64/1.11 768/1084 768/1084, 1.7 3 Recovered
J 93 F Unknown Unknown ~48 1.4 64/2.74 765/672 1497/1994, 1.8 9 Recovered
K 19 M 4 caps 12 29 Not drawn 18/0.92 89/151 113/184, 1.2 5 Recovered
L 19 M 8 caps 9 21 1.7 23/1.95 27/29 1404/2544, 2.1 5 Recovered
M†† 22 M 2 “shots” of mushroom juice and 3 (stalk and cap) <12 64 3.2 24/1.31 887/1326 2044/3351, 5.2 9 Recovered
N 22 M 1 “shot” of mushroom juice 4 64 1.7 18/0.94 6344/6400 6344/6400, 2.5 6 Recovered

Abbreviations: ALT = alanine transaminase; AST = aspartate transaminase; BUN = blood urea nitrogen; Cr = creatinine; F = female; INR = international normalized ratio; M = male.
* Normal lactate = 0.5–2.2 mmol/L.
Normal BUN = 7–20 mg/dL; normal Cr = 0.8–1.2 mg/dL.
§ Normal AST = 15–41 U/L; normal ALT = 17–63 U/L.
Normal INR = 0.8–1.2 units.
** Part of a single household cluster of five patients.
†† Discharged from initial hospital with diagnosis of gastroenteritis.

Suggested citation for this article: Vo KT, Montgomery ME, Mitchell ST, et al. Amanita phalloides Mushroom Poisonings — Northern California, December 2016. MMWR Morb Mortal Wkly Rep 2017;66:549–553. DOI:

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to